A Case Report of Massive Acetaminophen Poisoning Treated with a Novel “Triple Therapy”: N-Acetylcysteine, 4-Methylpyrazole, and Hemodialysis

Emily A. Kiernan,1 Julie A. Fritzges,1 Kathryn A. Henry,1 and Kenneth D. Katz1,2

1Department of Emergency and Hospital Medicine, Lehigh Valley Health Network and University of South Florida Morsani College of Medicine, Lehigh Valley Campus, Cedar Crest Boulevard & I-78, Allentown, PA 18103, USA
2University of South Florida Morsani College of Medicine, 12901 Bruce B. Downs Boulevard, Tampa, FL 33612, USA

Correspondence should be addressed to Kenneth D. Katz; kenneth_d.katz@lvhn.org

Received 31 August 2018; Revised 25 January 2019; Accepted 13 February 2019; Published 5 March 2019

Academic Editor: Aristomenis Exadaktylos

Massive acetaminophen (N-acetyl-p-aminophenol; APAP) ingestion is characterized by a rapid onset of mitochondrial dysfunction, including metabolic acidosis, lactemia, and altered mental status without hepatotoxicity which may not respond to the standard doses of N-acetylcysteine (NAC). A 64-year-old woman without medical history presented comatose after an ingestion of 208 tablets of Tylenol PM (APAP 500 mg and diphenhydramine 25 mg). The initial APAP concentration measured 1,017 μg/mL (therapeutic range 10-30 μg/mL), and elevated anion gap metabolic acidosis, lactemia, and 5-oxoprolinemia were detected. High-dose intravenous (IV) NAC, 4-methylpyrazole (4-MP), and hemodialysis (HD) were initiated. She was transferred to a liver transplant center and continued both NAC and HD therapies until complete resolution of metabolic acidosis and coma without developing hepatitis. She was discharged without sequelae. This is the fourth highest APAP concentration recorded in a surviving patient. Moreover, this is the first report of a novel “triple therapy” using NAC, 4-MP, and HD in the setting of massive APAP ingestion that presents with coma, elevated anion gap metabolic acidosis, and lactemia. Emergency physicians should recognize these critically ill patients and consider high-dose NAC, 4-MP, and HD to be initiated in the emergency department (ED).

1. Introduction

In the United States, APAP toxicity is the most common cause of acute hepatic failure and is the second most common cause of liver failure requiring transplantation. The Annual Report of the American Association Poison Control Centers’ National Poison Data System documented 49,417 cases of APAP exposure in 2016 and 21,776 cases of APAP combination medication exposure. APAP alone and APAP combinations resulted in 92 and 42 deaths, respectively [1].

Massive APAP ingestion is characterized by rapid onset of mitochondrial dysfunction, including metabolic acidosis, lactemia, and altered mental status without hepatotoxicity [2]. Metabolic acidosis in the setting of APAP poisoning is typically a late-onset process secondary to liver failure. However, when metabolic acidosis is present early after ingestion, it may be secondary to overwhelming N-acetyl-p-benzoquinone imine (NAPQI) presence. APAP can also cause 5-oxoprolinemia associated with depletion of liver glutathione stores and may contribute to metabolic acidosis early in clinical presentation, unassociated with liver failure [3, 4]. This is typically present when glutathione stores are exhausted, most often in those with genetic glutathione disorders and chronic APAP ingestion, but it has rarely been associated with acute toxicity [4, 5].

This case report details the case of a woman who intentionally ingested a massive amount of APAP and demonstrated both mitochondrial dysfunction and 5-oxoprolinemia contributing to metabolic acidosis, lactemia, and altered mental status. The authors of this paper suggest a novel approach to massive APAP toxicity through concomitant use of high-dose, IV NAC, 4-MP, and HD. This case represented
the fourth highest APAP concentration in the literature of a surviving patient, as well as the first known report of administering 4-MP—a CYP450 2E1 inhibitor—in the successful management [6].

2. Case Presentation

A 64-year-old woman with no past medical history and no prescribed medications was found unresponsive at home after ingestion of 208 tablets of Tylenol PM™ (APAP 500 mg with diphenhydramine 25 mg) approximately three hours prior to transportation to the ED. She was endotracheally intubated by prehospital staff due to decreased level of consciousness, vomitus, and agonal respiration. On arrival to the ED, vital signs included temperature of 33.9°C, heart rate of 57 bpm, blood pressure of 139/102 mmHg, respiratory rate of 19 rpm, and oxygen saturation of 99% on 100% FiO2. Physical examination demonstrated a Glasgow Coma Scale score 3 without spontaneous respiration. The patient subsequently became hypoten sive requiring five IV push-dose epinephrine doses (total 100 μg), followed by dopamine (10 μg/kg/min increased to 15 μg/kg/min), and then a norepinephrine infusion (10 μg/min). An electrocardiogram (ECG) showed sinus rhythm of 58 bpm, PR of 144 ms, QRS of 112 ms, and QTc of 659 ms. Serum chemistries measured as follows: lactate 7.6 mmol/L (0.5-1.0 mmol/L), glucose 193 mg/dL (70-100 mg/dL), Na+ 142 mEq/L (136-144 mEq/L), K+ 3.2 mEq/L (3.7-5.2 mEq/L), Cl− 110 mmol/L (96-106 mmol/L), CO2 18 mmol/L (20-29 mmol/L), BUN 16 mg/dL (7.20 mg/dL), Cr 1.17 mg/dL (0.6-1.1 mg/dL), AST 21 IU/L (10-34 IU/L), ALT 99 IU/L (8-37 IU/L), and INR 1.2 (0.8-1.1). Initial ABG measured as follows: pH 7.32 (7.35-7.45), pCO2 30 mmHg (35-45 mmHg), pO2 249 mmHg (80-100 mmHg), and HCO3− 16 (CMV FiO2 65%, PEEP 6, RR 16, and TV 500 mL). Initial serum APAP concentration measured 1,017 μg/mL. Serum salicylate and ethanol concentrations measured 7 mg/dL and negative, respectively. A preliminary urine drug screen of abuse detected only methadone. Expanded serum liquid chromatography/mass spectroscopy detected caffeine, dihydrocodeine/hydrocodol, lidocaine, monoethylglycinexilide, and diphenhydramine. A chest X-ray revealed mild interstitial edema. Head computed tomography was unremarkable. The patient was admitted to the intensive care unit. There was no repeat ECG performed prior to transfer to transplant center; however, no dysrhythmias were observed on telemetry monitoring.

The medical toxicology service was consulted and recommended IV sodium bicarbonate (for prolonged QRS interval), IV NAC, IV 4-MP (15 mg/kg), and immediate HD. APAP concentration decreased to 825 μg/mL after initiation of IV NAC, and serial concentrations exponentially decreased during “triple therapy” (Figures 1 and 2). During HD, the IV NAC rate of administration was doubled to 200 mg/kg and then tripled to 300 mg/kg, and a subsequent dose of IV 4-MP 10 mg/kg was administered; these were performed due to concern of HD removal of both antidotes.

The patient’s mental status improved during HD; however, she did not follow commands. Due to concern for potential severe liver injury given the massive initial APAP concentration and lack of institutional transplant services, she was transferred to a liver transplant center on hospital day one. On arrival to the liver transplant center, she was maintained on IV NAC and received an additional HD treatment. 4-MP was not re-administered. IV NAC was discontinued when APAP concentrations were undetectable. The patient was awake and following commands but failed extubation due to respiratory distress and pneumonia. She was ultimately extubated to BiPAP and discharged to an inpatient psychiatry unit approximately eight days after ED presentation in a normal state of health.

3. Discussion

Massive APAP ingestion results in saturation of hepatic sulfation and glucuronidation which leads to excessive metabolism via hepatic CYP450 2E1 to the toxic metabolite, NAPQI. NAPQI inhibits mitochondrial respiration and contributes to cellular toxicity and metabolic acidosis [2]. Accumulation of the organic acid, 5-oxoprolinemia, may also contribute to the metabolic acidosis. Although typically caused by genetic glutathione deficiencies, by chronic APAP use, or with coexisting conditions such as sepsis, malnutrition, or pregnancy, 5-oxoprolinemia may be present in acute, massive APAP ingestion alone [4, 5]. 5-Oxoprolinemia is an intermediate in the gamma-glutamyl pathway, responsible for regenerating glutathione and for transporting amino acid into the cytosol. Normal glutathione concentrations are required for negative feedback on the enzyme gamma-glutamyl cysteine synthase. When glutathione stores are depleted, there is overproduction of gamma-glutamyl cysteine, which is partially metabolized to 5-oxoproline, ultimately leading to acidosis. In this patient, given her coexisting 5-oxoprolinemia, it is logical that both NAPQI and organic acid accumulation contributed to her condition. The association with altered mental status after APAP ingestion with 5-oxoprolinemia has been reported [4, 5].

Standardly accepted treatment of APAP toxicity includes restoration of glutathione stores with NAC administration. However, given the considerable NAPQI formation in the setting of massive APAP ingestion, administration of a CYP450 2E1 substrate such as 4-MP or ethanol may lessen NAPQI formation and thus obviate significant cellular toxicity [7, 8]. 4-MP is a competitive antagonist of alcohol dehydrogenase and a potent CYP450 2E1 inhibitor that is used in the treatment of ethylene glycol and methanol toxicity. 4-MP has been studied as an alternative to NAC in rats with APAP-induced hepatotoxicity by Kucikardali et al. The authors compared the efficacy of NAC and 4-MP alone and in combination, ultimately concluding that the two xenobiotics have similar efficacy in limiting hepatotoxicity, as reflected by lower levels of serum transaminases and lesser degrees of hepatic necrosis [9]. In addition, a recent study by Akakpo et al. investigated the protective effect of 4-MP alone in treatment of APAP-induced liver injury in both mice and primary human hepatocytes. When 4-MP 50 mg/kg was administered with APAP 300 mg/kg, the expected severe liver injury after six hours was almost completely eliminated. In addition, the use of 4-MP resulted in inhibiting the formation of APAP-glutathione.
Figure 1

Management of massive APAP ingestion as a function of serum APAP concentration over time

Figure 2

APAP is amendable to elimination via HD due to its molecular weight of 151 Da, $V_d$ of 1 L/kg, and total protein binding of 10-30%. In addition, use of HD rapidly improves both severe metabolic derangement and APAP clearance [18]. Ghannoum et al. reported that HD doubles APAP clearance, and APAP half-life decreased from 5.2 hours to 1.9 hours. Clearance of NAC is also increased with HD and, thus, the recommended infusion rate is increased two to three times while the patient is on HD [2, 17, 19].

4. Conclusion

A novel “triple therapy” with NAC, 4-MP, and HD may be applicable and have physiologic merit in the case of a patient suffering from massive APAP poisoning. Further study is warranted.

Disclosure

The abstract titled “‘Triple Therapy’: Massive Acetaminophen Poisoning with Coma and Lactatemia successfully treated with N-Acetyl cysteine, Fomepizole, and Hemodialysis” was presented at the PA American College of Emergency Physicians’ 2018 Scientific Assembly.
Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Acknowledgments

The authors would like to acknowledge Lauren Crowley, BA, for her assistance in editing and formatting this case report.

References

[1] D. D. Gummin, J. B. Mowry, D. A. Spyker, D. E. Brooks, M. O. Fraser, and W. Banner, "2016 annual report of the american association of poison control centers’ national poison data system (NPDS): 34th annual report," Clinical Toxicology, vol. 55, no. 10, pp. 1072–1254, 2017.
[2] M. Ghannoum, S. Kazim, A. M. Grunbaum, E. Villeneuve, and S. Gosselin, "Massive acetaminophen overdose: effect of hemodialysis on acetaminophen and acetylcysteine kinetics," Clinical Toxicology, vol. 54, no. 6, pp. 519–522, 2016.
[3] M. Emmett, "Acetaminophen toxicity and 5-oxoproline (Pyroglutamic Acid): a tale of two cycles, one an ATP-depleting futile cycle and the other a useful cycle," Clinical Journal of the American Society of Nephrology, vol. 9, no. 1, pp. 191–200, 2014.
[4] D. T. Lawrence, L. K. Bechtel, N. P. Charlton, and C. P. Holstege, "5-oxoproline-induced anion gap metabolic acidosis after an acute acetaminophen overdose," The Journal of the American Osteopathic Association, vol. 110, no. 9, pp. 91–99, 2010.
[5] B. D. Humphreys, J. P. Forman, K. Zandi-Nejad, H. Bazari, J. Seifert, and C. C. Magee, "Acetaminophen-induced anion gap metabolic acidosis and 5-oxoprolineuria (pyroglutamic aciduria) acquired in hospital," American Journal of Kidney Diseases, vol. 46, no. 1, pp. 143–146, 2005.
[6] A. D. Shah, D. M. Wood, and P. I. Dargan, "Understanding lactic acidosis in paracetamol (acetaminophen) poisoning," British Journal of Clinical Pharmacology, vol. 71, no. 1, pp. 20–28, 2011.
[7] E. Hazai, L. Verezcky, and K. Monostory, "Reduction of toxic metabolite formation of acetaminophen," Biochemical and Biophysical Research Communications, vol. 291, no. 4, pp. 1089–1094, 2002.
[8] S. S. T. Lee, J. T. M. Buters, T. Pineau, P. Fernandez-Salgueiro, and F. J. Gonzalez, "Role of CYP2E1 in the hepatotoxicity of acetaminophen," The Journal of Biological Chemistry, vol. 271, no. 20, pp. 12063–12067, 1996.
[9] Y. Küçükdalı, U. Cihan, H. V. Acar, and P. D. Shah, "Comparison of the therapeutic efficacy of 4-methylpyrazole and N-acetylcysteine on acetaminophen (paracetamol) hepatotoxicity in rats," Current Medical Research and Opinion, vol. 18, no. 2, pp. 78–81, 2002.
[10] J. Akakpo, A. Ramachandran, S. Kandel et al., "4-Methylpyrazole protects against acetaminophen hepatotoxicity in mice and in primary human hepatocytes," Human & Experimental Toxicology, vol. 37, no. 12, pp. 1310–1322, 2018.
[11] K. McMartin, K. E. Hovda, and D. Jacobsen, Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient, J. Brent, Ed., Springer, New York, NY, USA, 2nd edition, 2017.
[12] D. Lucas, C. Ménez, C. Girre, P. Bodézé, E. Hispard, and J. Ménez, "Decrease in cytochrome P4502E1 as assessed by the rate of chlorozaaxone hydroxylation in alcohols during the withdrawal phase," Alcoholism: Clinical and Experimental Research, vol. 19, no. 2, pp. 362–366, 1995.
